Introduction
Asthma is now widely accepted as an in¯ammatory disease and is characterized by hyperresponsiveness of the pulmonary airways to stimuli such as histamine, as well as by an increased population of in¯ammatory cells in both the submucosal area and lumen exudate, comprised predominantly of eosinophils. We have previously shown that rabbits immunized with Alternaria tenuis antigen at birth and repeatedly exposed to this antigen during the ®rst 3 months of life develop persistent airway hyperresponsiveness and an increased presence of in¯ammatory leukocytes in the bronchoalveolar lavage¯uid (Herd et al., 1994) . Studies have demonstrated that immunization of neonatal rabbits induces the production of predominantly IgE antibodies (Pinckard et al., 1972; Shampain et al., 1982) . As adults, these rabbits display both early-and late-onset airways obstruction associated with airway in¯ammation following antigen challenge (Shampain et al., 1982; Larsen et al., 1987; Coyle et al., 1989; 1990) .
One of the predominant in¯ammatory cells present in the lung in asthma is the mast cell which is activated by crosslinking of IgE and pharmacological stimuli such as calcium ionophores to cause degranulation with the subsequent release into the surrounding tissue of histamine and other mediators (reviewed in . Degranulation of mast cells results in the release of the glycosaminoglycan heparin (Lasser et al., 1987; Green et al., 1993) which is synthesized and stored in these cells (Selye, 1965; Bloom, 1974) . It is released along with histamine upon activation of the mast cells. Heparin is also known to have an inhibitory eect on mast cell degranulation (Ahmed et al., 1994) which may act as a regulatory mechanism. Natural heparin-like compounds exist as heparan sulphate and occur primarily as a component of proteoglycans when the structurally heterogeneous glycosaminoglycan polymers are covalently linked to a core protein.
Heparan sulphate proteoglycans are widely present on cell surfaces (Hook et al., 1984) bound to components of the extracellular matrix and in basal lamina (reviewed in Conrad, 1989) .
Although its anticoagulant activity is well documented, heparin is also known to possess a range of other activities (Tyrrell et al., 1995) including activation of macrophages to become scavengers (Dolowitz & Dougherty, 1965) , inhibition of vascular leakage induced by histamine, bradykinin and PGE 1 (Carr, 1979) and to induce lymphocytosis (Sasaki, 1967) . It is also known to decrease myointimal thickening and vascular smooth muscle cell proliferation (Clowes & Karnovsky, 1977; Hirsch & Karnovsky, 1991) . In addition to these varied activities it has long been known that heparin inhibits the allergic anaphylactic response (Van der Carr & Williams, 1928) .
Previous studies in our laboratory have demonstrated that heparin and related heparinoids inhibit airway hyperresponsiveness and pulmonary cell in®ltration induced by PAF in the rabbit and guinea-pig and by allergen in the guinea-pig (Seeds et al., 1995) . Therefore, in the present study, we have investigated the eect of heparin, low molecular weight heparin (LMWH) and the linear polyanionic molecule, polyglutamic acid (PGA), given both prior to and immediately following antigen challenge on antigen-induced airway hyperresponsiveness and in¯ammatory leukocyte in®ltration in rabbits.
Methods

Animals
New Zealand White (NZW) rabbits (Frox®eld Farms, Peters®eld, Hampshire, U.K.) of either sex were used in this study. The immunization protocol is that described previously whereby rabbits were injected intraperitoneally within 24 h of birth with 0.5 ml of Alternaria tenuis extract in aluminium hydroxide and saline in the ratio 2 : 1 : 1. Further administration followed on a weekly basis for the next month and then on a biweekly basis for a further 2 months.
Pulmonary function measurements
At 3 months of age, immunized rabbits were premedicated with diazepam (2.5 mg.kg 71 , i.p.) and subsequently administered Hypnorm (0.4 ml.kg 71 , i.m.). This reÂ gime produces neuroleptanalgesia and is recommended for recovery procedures in laboratory animals (Flecknall, 1987) . Throughout the course of the experiments, neuoleptanalgesia was maintained by further administration of 0.5 ml Hypnorm intramuscularly at 25 ± 30 min intervals. Animals were intubated with a cued endotracheal tube (3.0 mm internal diameter; Mallinckrodt Laboratories, Athlone, Ireland) which was then in¯ated and attached to a heated (378C) Fleisch pneumotachograph (size 00). Respiratory¯ow, pleural pressure, transpulmonary pressure and tidal volume were measured according to the methods previously described . Total lung resistance (R L ) and dynamic compliance (C dyn ) were calculated by an online respiratory analyser (PMS Version 5.2; Mumed Ltd, London, U.K.).
Aerosols of drugs and antigen were generated by an ultrasonic nebulizer (Ultra-Neb 99; DeVilbiss Health Care Ltd, Heston, Middlesex, U.K.) and delivered to the animal via the tracheal cannula.
Experimental protocol
Experiments were conducted over a period of three consecutive days with recovery of animals following days 1 and 2. On day 1, following measurements of lung function for baseline and aerosolized saline, airway hyperresponsiveness to histamine was determined. Aerosolized histamine was given in doubling, cumulative concentrations of 1.25 ± 160 mg.ml 71 for a period of 2 min per concentration with lung function measurements taken between each dose. Cumulative concentration-eect curves were thus established and the provocation concentration (PC) of histamine which cumulatively produced a 50% increase in R L (PC 50 ) or a 35% fall in C dyn (PC 35 ) was determined for each animal. These values were used as indices of airway responsiveness.
On day 2, animals were administered either heparin (Multiparin; 1000 U.ml 71 or 5000 U.ml 71 ), low molecular weight heparin (LMWH; 1000 U.ml 71 ), polyglutamic acid (5 mg.ml 71 ) or vehicle (chlorocresol or saline) in aerosolized form for 2 min, 20 min prior to antigen challenge or immediately following the last administration of antigen. Antigen challenge consisted of an initial administration of aerosolized saline for 2 min, followed by aerosolized Alternaria tenuis (20,000 PNU.ml
71
) for 262 min periods with a further 464 min periods, resulting in a total of 20 min of antigen challenge. Lung function measurements were made following each aerosolization and then again 15 and 30 min following the ®nal antigen aerosol challenge. In animals administered with the treatment drugs following the ®nal antigen challenge, a further lung function measurement was made following the administration of the drug. On day 3, histamine challenge was repeated as for day 1.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed immediately following histamine concentration-eect curves on days 1 and 3. This involved the administration of 5 ml saline via the endotracheal tube with immediate aspiration and collection into a sterile tube on ice. Total cell counts were determined under light microscopy using an improved Neubauer haemocytometer. Dierential cell counts of neutrophils, eosinophils and mononuclear cells were also determined from cytospin preparations as previously described .
Data analysis
Acute changes in airway responsiveness following drug administration or antigen challenge are expressed as the maximum percentage change in R L and C dyn from baseline. Unpaired Student's t-tests were used to compare dierences between treatment groups.
Cumulative concentration-eect curves to histamine were constructed for all animals on days 1 and 3. Curves were compared using 2-way analysis of variance (ANOVA 
Results
Airway responses
Basal lung function In animals given drug treatment prior to antigen challenge, basal airway resistance (R L ) and dynamic compliance (C dyn ) were similar between the dierent groups of animals 24 h prior to antigen challenge, immediately prior to challenge, or 24 h post challenge. The only exceptions were that observed in the R L group for heparin (5000 U.ml 71 ) which demonstrated a small but signi®cant variation in baseline values from that obtained 24 h prior to antigen and a signi®cant decrease in values observed for the C dyn group for PGA (Table 1) .
In animals treated following antigen challenge, basal airway resistance (R L ) and dynamic compliance (C dyn ) values were not signi®cantly dierent (P40.05; 1-way ANOVA) across the treatment groups for any of the days (24 h prior, challenge or 24 h post challenge) examined (Table 2 ). In addition, within the groups, basal resistance and compliance remained similar over the 3 days of the experimental protocol except in the case of C dyn for heparin (5000 U.ml 71 ) and both R L and C dyn for chlorocresol (0.15%) ( Table 2) .
The acute eects of drug administration on lung responses were determined as R L and C dyn measured 1 and 20 min following aerosol administration of saline, heparin vehicle, heparin (1000 U.ml 71 and 5000 U.ml
71
), LMWH (1000 U.ml 71 ) or PGA (5 mg.ml 71 ) prior to antigen challenge. Values measured 20 min following aerosol administration of drugs were largely unaltered compared to the values obtained 1 min following drug administration. The obvious exception to this was the baseline %DC dyn results obtained for PGA which were signi®cantly lower after 20 min compared to after 1 min (Table 3) .
In animals treated with drugs following antigen challenge, lung function responses were determined 1 min following aerosol administration of the drugs. There was no signi®cant dierence between any of the treatment drugs and their corresponding vehicles.
Acute bronchoconstriction
In animals administered with the drugs prior to antigen challenge, acute antigen-induced bronchoconstriction, determined as a percentage increase in total lung resistance and decrease in dynamic compliance and measured during the antigen challenge and for the following 30 min, was not signi®cantly dierent in vehicle-treated or drug-treated animals Values are presented as the mean of n animals + the standard error of the mean. *Indicates data signi®cantly dierent (P50.05: 1-way ANOVA) across the group comprising 24 h prior, challenge and 24 h post challenge data.
British Journal of Pharmacology, vol 129 (8) Data represented as the mean of n animals+standard error of the mean. Values are presented as the mean of n animals+the standard error of the mean. *Indicates data signi®cantly dierent (P50.05; Students t-test of paired data) to the pre-antigen value. Values are presented as the mean of n animals+the standard error of the mean. *Indicates data signi®cantly dierent (P50.05; Students t-test of paired data) to the corresponding vehicle.
British Journal of Pharmacology, vol 129 (8) (Table 4 ). In animals administered with the drugs following antigen challenge, acute antigen-induced bronchoconstriction was similarly unchanged in drug-treated animals compared to the corresponding vehicle-treated animals (Table 4) .
Airway responsiveness to histamine
Prior to antigen challenge, responsiveness to histamine was similar in terms of R L PC 50 and C dyn PC 35 in all groups (Tables 5  and 6 ). In animals treated with saline prior to antigen challenge, airway hyperresponsiveness was demonstrated by a signi®cant decrease in R L PC 50 in addition to a signi®cant increase in maximum airway resistance (Figure 1a) . Similarly, the cumulative concentration-eect curves for histamine C dyn had a signi®cantly lower C dyn PC 35 with a decreased minimum dynamic compliance (Figure 1b ). These changes in airway responsiveness to histamine were quantitatively observed as a 3.3 fold decrease in R L PC 50 and a 3.4 fold decrease in C dyn PC 35 (Table 5 ). Similar changes in the responsiveness of the rabbit airways to histamine in terms of both R L and C dyn were observed in animals treated with the heparin vehicle at both concentrations examined (0.03 and 0.15%) and were highly Figure 1 Cumulative concentration-eect curves described in terms of (a,c) increase in airway resistance (%R L ) and (b,d) decrease in dynamic compliance (%C dyn ) from basal levels in response to aerosolized histamine prior to and following antigen challenge in animals that were treated with saline prior to (a,b) and following (c,d) antigen challenge. Data presented as the mean+standard error of the mean from 12 and 8 animals respectively.
British Journal of Pharmacology, vol 129 (8) signi®cant with P50.0001 in all cases (Figures 2 and 3 ). Animals treated with the heparin vehicles (chlorocresol 0.03 and 0.15%) also demonstrated signi®cant changes in R L PC 50 and C dyn PC 35 (Table 5) . In animals treated with saline following antigen challenge, there was no signi®cant dierence in the cumulative concentration eect curve to histamine following antigen challenge compared to that prior to antigen challenge ( Figure  1c,d) . Conversely, in animals treated with the heparin vehicles (chlorocresol 0.03 and 0.15%) following antigen challenge, there was a signi®cant (P50.05; 2-way ANOVA) alteration in the concentration-eect curves to histamine following antigen challenge compared to that prior to antigen challenge ( Figures  2 and 3 ). Despite these changes in the histamine curves, only Figure 2 Cumulative concentration-eect curves described in terms (a,c) increase in airway resistance (%R L ) and (b,d) decrease in dynamic compliance (%C dyn ) from basal levels in response to aerosolized histamine prior to antigen challenge and following antigen challenge in animals treated with either heparin (1000 U.ml (Table 6) .
In animals treated with heparin (1000 U.ml 71 ) prior to antigen challenge, the antigen-induced change in the cumulative concentration-eect curves to histamine observed in saline-or vehicle-treated animals was abolished (Figure 2 ). The R L PC 50 and C dyn PC 35 values determined from the curves following antigen challenge were not signi®cantly dierent from those prior to antigen challenge (Table 5) Treatment of animals with heparin (1000 U.ml
71
) following antigen challenge did not alter the signi®cant (P50.05; 2-way ANOVA) change in the histamine concentration-eect curve that was observed in vehicle-treated animals, although only the PC 35 C dyn reached statistical signi®cance (Table 6 ). Conversely, animals administered heparin (5000 U.ml 71 ) following antigen challenge demonstrated a statistically signi®cant alteration in the histamine concentration-eect curve for C dyn , but not for RL (Figure 3 ) and neither the R L PC 50 nor the C dyn PC 35 reached statistical signi®cance (P40.05; Student's paired t-test).
Aerosol administration of LMWH (1000 U.ml 71 ) prior to antigen challenge also resulted in a signi®cant dierence in the cumulative concentration-eect curves for histamine R L but not for C dyn (Figure 4 ) although R L PC 50 and C dyn PC 35 values were not signi®cantly dierent prior to and following antigen challenge (Table 5 ). The disparity of these results is due to the greater change in the curves at the higher concentrations of histamine than at the lower dose range, resulting in a¯atter shape to the concentration-eect curve (Figure 4) . Similar changes in the cumulative concentrationeect curves for histamine R L but not for C dyn ( Figure 5 ) were observed in animals treated with PGA, (5 mg.ml
) and in this case, the R L PC 50 and C dyn PC 35 values re¯ected these changes (Table 5 ). PC 50 values for airway resistance (R L ) prior to and following antigen challenge were signi®cantly dierent for LMWH and PGA-treated animals in animals treated with the drugs following antigen challenge (Table 6 ). Analysis of the cumulative concentration-eect curves to histamine indicated a signi®cant (P50.05; 2-way ANOVA) change in the R L curve following antigen challenge in those animals treated with LMWH ( Figure 4c ). PC 35 values for dynamic compliance (C dyn ) prior to and following antigen challenge were also signi®cantly dierent in animals treated with LMWH and a clear dierence (P50.05; 2-way ANOVA) in the cumulative concentration-eect curves was observed (Figure 4d ). Whilst not reaching statistical signi®cance, a clear trend towards an alteration in the C dyn cumulative concentration eect curve could be seen after antigen challenge in animals treated with PGA ( Figure 5 ).
Bronchoalveolar lavage
The volume of¯uid recovered from BAL was not signi®cantly dierent between drug and vehicle-treated rabbits before or after antigen challenge (2.0 ± 4.0 ml, 40 ± 80% recovery). Total and dierential cell counts prior to antigen challenge were similar in all groups of animals. Following antigen challenge in rabbits treated with saline prior to antigen challenge, there was no change in total or mononuclear cell numbers but neutrophil and eosinophil numbers were increased 41 fold and 37 fold respectively above that obtained 24 h prior to antigen challenge (Table  7) . Drug-treated groups of animals did not have signi®cantly dierent neutrophil or eosinophil numbers following antigen challenge from that of the corresponding saline or vehicle control groups.
In animals treated with saline following antigen challenge, there was no change in total or mononuclear cell numbers but neutrophil and eosinophil numbers were increased 28 fold and 139 fold respectively (Table 8) . Drug-treated groups of animals did not have signi®cantly dierent neutrophil or eosinophil numbers following antigen challenge from that of the corresponding saline or vehicle control groups.
Discussion
The present study has demonstrated that aerosolized heparin dierentially inhibits the development of airway hyperresponsiveness but not the associated in¯ammatory leukocyte in¯ux into the airways, depending on whether it is administered prior to or following antigen challenge of actively sensitized rabbits.
There is con¯icting evidence concerning the relationship between the presence of in¯ammatory cells in the airways and the development of airway hyperresponsiveness (Brusasco et al., 1998) . Whilst the exact mechanism of action responsible for the development of airway hyperresponsiveness is unknown (LoÈ tvall et al., 1998) , mast cells are known to play a role through the release of secondary mediators such as histamine, prostaglandin D 2 , leukotrienes, cytokines and platelet-activating factor (PAF) (Harvima & Schwartz, 1993; . Heparin, whilst synthesized, stored and released from mast cells (Selye, 1965; Bloom, 1974; Lasser et al., 1987; Green et al., 1993) , is also known to have an inhibitory eect on mast cell degranulation (Ahmed et al., 1994) . It is plausible therefore that administration of heparin prior to allergen challenge may prevent the degranulation of the mast cells and thus inhibit the secondary release of mediators which may be responsible, at least in part, for the development of airway hyperresponsiveness. Indeed it has long been known that heparin inhibits the allergic anaphylactic response (Van der Carr & Williams, 1928) .
More recent studies have demonstrated that heparin can modulate the activities of a number of in¯ammatory cells (Tyrrell et al., 1995) . It has previously been shown that heparin inhibits the adhesion of leukocytes to the endothelium (Rogers et al., 1993) most likely by displacing pro-adhesive cytokines (which are responsible for the formation of cell adhesion complexes) from the luminal surface of the endothelium (Tanaka et al., 1993a,b) . Preliminary studies in our laboratory have demonstrated that intravenously administered heparin and related heparinoids inhibit airway hyperresponsiveness and pulmonary cell in®ltration induced by PAF in the rabbit and guinea-pig . Clinical studies examining the eectiveness of inhaled heparin have produced mixed results with some studies demonstrating a signi®cant inhibition of exercise-induced bronchoconstriction (Ahmed et al., 1993a) , the early response to house dust mite (Bowler et al., 1993) and the late asthmatic response to allergens (Weersink et al., 1994; Diamant et al., 1996) , whilst others have been unable to demonstrate any signi®cant attenuation of allergen-induced acute bronchoconstriction following heparin (O'Donnell et al., 1992) or the responses to sodium metabisulphite and methacholine challenge (Pavord et al., 1996) .
The present study has examined the eect of pretreatment with aerosolized heparin, low molecular weight heparin (LMWH) and the polyanionic molecule, polyglutamic acid (PGA) on the development of airway hyperresponsiveness in an established animal model. The results demonstrate that following antigen challenge of actively sensitized animals treated with either saline or vehicle, the histamine concentration-eect curves for R L and C dyn are signi®cantly altered, as evidenced by a signi®cant increase in the R L PC 50 and a signi®cant decrease in the C dyn PC 35 values, concurrent with an increase in the maximal responses obtained. These data demonstrate the development of airway hyperresponsiveness to histamine following antigen challenge in these animals. Following pretreatment with heparin or LMWH prior to antigen challenge however, the airway hyperresponsiveness to histamine is signi®cantly inhibited. These results are in agreement with previous studies in the sheep (Ahmed et al., 1992; where aerosol administration of heparin inhibited the development of airway hyperresponsiveness.
In those animals treated with heparin immediately following antigen challenge, the hyperresponsiveness to histamine in terms of changes in R L and C dyn was still evident in animals treated with the lower dose (1000 U.ml 71 ) of heparin. At the higher dose (5000 U.ml 71 ) of heparin, hyperresponsiveness was still observed in C dyn , but was not evident in R L . This latter result is most likely due to the large variation surrounding the data, as there is a clear trend towards a change in the curve following antigen challenge.
Administration of LMWH to the animals immediately following antigen challenge did not inhibit the development of hyperresponsiveness to histamine. This is in contrast to the results obtained when LMWH was administered prior to antigen challenge and suggests that the timing of the administration of LMWH is important in inhibiting the development of hyperresponsiveness to histamine in actively sensitized rabbits.
The linear polyanionic molecule, PGA, was used to determine whether the large negative charge of the heparin molecule may be responsible for the results obtained. When given prior to antigen challenge, PGA inhibited the change in R L following antigen challenge, but did not signi®cantly inhibit the change in C dyn . This latter result may be due to the signi®cantly decreased baseline values for C dyn observed 20 min after administration of PGA, the reasons for which are unknown. The results obtained from animals treated with PGA following antigen challenge were similar to that obtained when PGA was administered prior to antigen challenge, except that the R L curves were not signi®cantly dierent in animals treated following antigen challenge. These results therefore, suggest that the large negative charge associated with heparin is unlikely to be responsible for the inhibition of hyperresponsiveness observed following treatment with heparin.
Previous studies Seeds et al., 1993 ) have demonstrated a PAF-induced increase in eosinophil and neutrophil numbers in the BAL. Similarly, the present study has demonstrated a signi®cant increase in antigeninduced neutrophil and eosinophil numbers in saline or vehicle-treated rabbits. In contrast to previous studies whereby heparin was administered intravenously Seeds et al., 1993) , the aerosol administration of heparin, LMWH and PGA in the present study failed to inhibit eosinophil and neutrophil in®ltration following antigen challenge. In a study using a guinea-pig model of airway hyperresponsiveness, inhaled heparin inhibited eosinophil in®ltration only at the highest administered dose and had no signi®cant eect on neutrophil in®ltration (Seeds et al., 1995) . The failure of inhaled heparin to inhibit in¯ammatory cell in®ltration into the airways is most likely due to diculties in the penetration of these drugs into the circulation in concentrations sucient to inhibit the migration of in¯ammatory cells. The ability of heparin and LMWH to inhibit the development of airway hyperresponsiveness whilst failing to inhibit the in¯ux of in¯ammatory cells into the airways is in line with other studies (Herd et al., 1995) which have suggested that the presence of in¯ammatory cells in the airways is not necessarily a pre-requisite to the development of airway hyperresponsiveness.
In conclusion, the present study has demonstrated that heparin and LMWH can inhibit the development of airway hyperresponsiveness to histamine in a rabbit model. The linear polyanionic molecule, PGA was not as eective in inhibiting the airway hyperresponsiveness to inhaled histamine, suggesting that the inhibitory eects of heparin and LMWH are not due entirely to their anionic nature. In addition, the failure of these drugs to inhibit the in¯ammatory cell in¯ux into the airway tissue suggests that the presence of in¯ammatory cells into the airways is not a pre-requisite to the development of airway hyperresponsiveness.
